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In recent years, activation of the patient’s immune system
to defend against tumors was demonstrated to be a pro-
mising alternative strategy to classical cancer treatments.
Dendritic cells (DCs) can present antigens on MHC-II
and -I leading to the activation of CD4+ or CD8+ T cells,
respectively. Stimulated CD4+ T cells act as helper cells
for cytotoxic CD8+ T cells to kill tumor cells by mediat-
ing strong proliferation and licensing DCs, increasing
their presentation capacity. Tumors bearing MHC-II
molecules can also be directly destroyed by cytotoxic
CD4+ T cells. As an efficient anti-tumor response
strongly depends on the interplay of DCs, CD4+ and
CD8+ T cells, these three cell types are considered to be
essential for successful immunotherapy design.
In clinical trials, DCs were either endogenously or exo-
genously loaded with tumor antigens for the presentation
on MHC-I rather MHC-II. As the antigen presentation
pathways differ, a simultaneous loading of MHC-I and -II
was suboptimal. To overcome this obstacle, we used a
signaling sequence (CrossTAg) to force MHC-II cross-
presentation of tumor-associated antigens (TAAs)
encoded by in vitro transcribed (ivt) RNA. Subsequently,
peripheral blood lymphocytes were primed by DCs expres-
sing TAAs on MHC-I and -II enabling activation and
interaction of CD4+ and CD8+ T cells. By this approach,
we were able to induce and identify TAA-specific CD4+
and CD8+ T cells in the same experiment.
In addition, superior induction efficiency of DCs
loaded with CrossTAg-TAA-ivtRNA compared to con-
ventional TAA-ivtRNA was shown in the humanized
NOD/scid IL2Rgnull (NSG) mouse model. NSG mice
were engrafted with human peripheral blood mononuclear
cells (PBMC) and vaccinated twice with DCs either trans-
fected with CrossTAg-TAA-ivtRNA or conventional
TAA-ivtRNA. Reisolated PBMC of mice vaccinated with
CrossTAg-TAA-ivtRNA transfected DCs showed higher
numbers of antigen-specific CD8+ T cells and stronger
activation/cytotoxic activity against tumor cells.
These in vitro and in vivo data illustrate the benefits
of loading DCs with CrossTAg-linked target antigens as
CD8+ and CD4+ T cells can be induced side by side
allowing interactions and T cell help.
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